eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial.
about
Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancerCirculating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab.IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patientsRight- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab EfficacyDihydroartemisinin increases apoptosis of colon cancer cells through targeting Janus kinase 2/signal transducer and activator of transcription 3 signaling.
P2860
eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial.
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
eNOS polymorphisms as predicto ...... m a randomized clinical trial.
@ast
eNOS polymorphisms as predicto ...... m a randomized clinical trial.
@en
type
label
eNOS polymorphisms as predicto ...... m a randomized clinical trial.
@ast
eNOS polymorphisms as predicto ...... m a randomized clinical trial.
@en
prefLabel
eNOS polymorphisms as predicto ...... m a randomized clinical trial.
@ast
eNOS polymorphisms as predicto ...... m a randomized clinical trial.
@en
P2093
P2860
P50
P921
P1476
eNOS polymorphisms as predicto ...... m a randomized clinical trial.
@en
P2093
Bernadette Vertogen
Davide Tassinari
Dino Amadori
Giorgia Marisi
Giovanni Luca Frassineti
Stefano Tamberi
Wainer Zoli
P2860
P2888
P356
10.1186/S12967-015-0619-5
P577
2015-08-11T00:00:00Z
P5875
P6179
1010938122